- Home
- MTEM vs PRPO Comparison
MTEM vs PRPO Comparison
Compare MTEM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEM
- PRPO
- Stock Information
- Founded
- MTEM 2001
- PRPO N/A
- Country
- MTEM United States
- PRPO United States
- Employees
- MTEM N/A
- PRPO 57
- Industry
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- MTEM Health Care
- PRPO Industrials
- Exchange
- MTEM Nasdaq
- PRPO Nasdaq
- Market Cap
- MTEM 9.7M
- PRPO 9.5M
- IPO Year
- MTEM N/A
- PRPO N/A
- Fundamental
- Price
- MTEM $0.71
- PRPO $6.59
- Analyst Decision
- MTEM
- PRPO
- Analyst Count
- MTEM 0
- PRPO 0
- Target Price
- MTEM N/A
- PRPO N/A
- AVG Volume (30 Days)
- MTEM 13.4M
- PRPO 7.9K
- Earning Date
- MTEM 11-11-2024
- PRPO 11-11-2024
- Dividend Yield
- MTEM N/A
- PRPO N/A
- EPS Growth
- MTEM N/A
- PRPO N/A
- EPS
- MTEM N/A
- PRPO N/A
- Revenue
- MTEM $25,470,000.00
- PRPO $16,719,999.00
- Revenue This Year
- MTEM N/A
- PRPO $75.18
- Revenue Next Year
- MTEM N/A
- PRPO N/A
- P/E Ratio
- MTEM N/A
- PRPO N/A
- Revenue Growth
- MTEM N/A
- PRPO 52.61
- 52 Week Low
- MTEM $0.30
- PRPO $4.31
- 52 Week High
- MTEM $6.48
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- MTEM 38.68
- PRPO 52.82
- Support Level
- MTEM $0.31
- PRPO $6.42
- Resistance Level
- MTEM $1.34
- PRPO $6.99
- Average True Range (ATR)
- MTEM 0.14
- PRPO 0.33
- MACD
- MTEM -0.05
- PRPO -0.04
- Stochastic Oscillator
- MTEM 34.48
- PRPO 69.91
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.